Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep

# Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep ## Overview Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep is a combination medication containing tenofovir disoproxil fumarate and emtricitabine. It is a nucleoside reverse transcriptase inhibitor (NRTI) and a nucleotide reverse transcriptase inhibitor (NtRTI). ## Primary Indications * Treatment of HIV-1 infection in adults and pediatric patients. ## Adult Dosing * One tablet (200 mg emtricitabine/300 mg tenofovir disoproxil fumarate) orally once daily. ## Pediatric Dosing * For pediatric patients weighing at least 10 kg to less than 15 kg: 7.5 mg emtricitabine/5 mg tenofovir disoproxil fumarate per kg orally once daily. * For pediatric patients weighing at least 15 kg to less than 20 kg: 5 mg emtricitabine/3.3 mg tenofovir disoproxil fumarate per kg orally once daily. * For pediatric patients weighing at least 20 kg to less than 25 kg: 3.75 mg emtricitabine/2.5 mg tenofovir disoproxil fumarate per kg orally once daily. * For pediatric patients weighing 25 kg or greater: One tablet (200 mg emtricitabine/300 mg tenofovir disoproxil fumarate) orally once daily. * **Note:** Pediatric dosing may involve alternative formulations based on weight and age, and specific prescribing information should be consulted. ## Dose Adjustments * No dose adjustment is required for patients with mild to moderate renal impairment. * Dosing interval adjustment is necessary for patients with severe renal impairment. Consult prescribing information for specific interval recommendations. * Discontinue if the estimated creatinine clearance (CrCl) is less than 30 mL/min. ## Contraindications * Hypersensitivity to emtricitabine, tenofovir disoproxil fumarate, or any component of the formulation. ## Adverse Effects * **Common:** Diarrhea, nausea, headache, fatigue, rash, dizziness, depression. * **Serious:** Lactic acidosis (potentially fatal), severe hepatomegaly with steatosis, redistribution or accumulation of body fat, immune reconstitution inflammatory syndrome (IRIS), new onset or worsening renal impairment (including acute renal failure and Fanconi syndrome), bone mineral density loss. ## Key Drug Interactions * **Nephrotoxic agents:** Concomitant use with drugs that are potentially nephrotoxic (e.g., NSAIDs, certain antivirals like adefovir dipivoxil, diuretics) may increase the risk of renal-related adverse events. * **Didanosine:** Concomitant use with didanosine may increase didanosine concentrations and increase the risk of didanosine-related adverse events, including pancreatitis and neuropathy. * **Hepatitis B virus (HBV) treatment:** Discontinuation of emtricitabine and tenofovir disoproxil fumarate in patients coinfected with HIV-1 and HBV may result in severe acute exacerbations of hepatitis B. ## Monitoring * Renal function (serum creatinine, CrCl, urinalysis) at baseline and periodically during treatment. * Liver function tests (ALT, AST, bilirubin) at baseline and periodically during treatment. * Lipid profiles. * Bone mineral density in patients with a history of fractures or other risk factors for osteoporosis or bone disease. * Signs and symptoms of lactic acidosis and steatosis. * HIV viral load and CD4+ T-cell count. * Hepatitis B surface antigen (HBsAg) and HIV antibody testing in coinfected patients upon discontinuation. ## Clinical Pearls * Can be taken with or without food. * Due to the risk of renal impairment, caution is advised when used in combination with other nephrotoxic medications. * Emphasize adherence to therapy for optimal viral suppression and prevention of drug resistance. * For patients with HBV coinfection, monitoring for hepatic flares upon discontinuation is critical. *** **Disclaimer:** This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines to ensure appropriate patient care.